In recent years, a number of studies have reported that the aberrant activation of Nrf2 enhances the resistance of esophageal squamous cell carcinoma (ESCC) to chemoradiotherapy (CRT) [7–9]. The gene discussed is NFE2L2; the disease is esophageal squamous cell carcinoma.